Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Net Profit Margin
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Pfizer Inc., net profit margin, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The net profit margin exhibited considerable fluctuation between 2005 and 2025. Initial values demonstrated strong profitability, followed by periods of decline and substantial recovery, culminating in a recent period of volatility.

Initial Period (2005-2006)
From 2005 to 2006, the net profit margin increased significantly, rising from 15.76% to 39.98%. This represents a substantial improvement in profitability, potentially driven by increased efficiency or favorable market conditions.
Stabilization and Moderate Fluctuations (2007-2010)
Following 2006, the net profit margin experienced a period of relative stabilization, fluctuating between 16.82% and 17.27% from 2007 to 2009. A decline to 12.18% was observed in 2010, suggesting a potential shift in cost structure or revenue generation.
Recovery and Peak (2011-2013)
The net profit margin recovered from 2011 to 2013, increasing from 14.84% to a peak of 42.65% in 2013. This period indicates a strong return to profitability, potentially linked to successful product launches or cost management initiatives.
Subsequent Decline and Volatility (2014-2015)
A notable decline in the net profit margin occurred between 2013 and 2015, falling from 42.65% to 14.25%. This suggests increased costs or decreased revenue, impacting overall profitability. The margin remained relatively stable at 13.66% in 2016.
Significant Increase and Subsequent Adjustment (2017-2020)
The net profit margin experienced a dramatic increase in 2017, reaching 40.55%, followed by a decrease to 20.79% in 2018 and a further increase to 31.45% in 2019. In 2020, the margin settled at 22.53%. This period demonstrates considerable volatility, potentially influenced by specific events or strategic decisions.
Recent Performance (2021-2025)
From 2021 to 2025, the net profit margin showed further fluctuation. It rose to 26.76% in 2021 and 31.01% in 2022, before experiencing a substantial decrease to 3.56% in 2023. A partial recovery was observed in 2024 and 2025, with margins reaching 12.62% and 12.42% respectively. This recent volatility suggests potential challenges in maintaining consistent profitability.

Overall, the net profit margin demonstrates a pattern of significant swings rather than consistent growth. While periods of high profitability were achieved, these were interspersed with periods of decline, indicating sensitivity to external factors or internal operational changes. The recent decline in 2023 warrants further investigation to understand the underlying causes and potential implications for future performance.


Comparison to Competitors

Pfizer Inc., net profit margin, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Pfizer Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)